NeuroPace Inc Chief Medical Officer Martha Morrell Sells 13,848 Shares
NeuroPace Inc (NASDAQ:NPCE), a company specializing in the development and commercialization of implantable devices designed to treat neurological disorders through responsive neurostimulation, has reported an insider sell transaction. According to a recent SEC filing, the insider, Chief Medical Officer Martha Morrell, sold 13,848 shares of the company on February 1, 2024.
Over the past year, the insider has sold a total of 41,813 shares and has not made any purchases of the stock. The recent transaction is part of a trend observed over the past year, where there have been no insider buys and eight insider sells for NeuroPace Inc.
On the date of the sale, shares of NeuroPace Inc were trading at $15.09, valuing the company at a market cap of approximately $393.992 million.
The stock's valuation, when compared to the GuruFocus Value (GF Value) of $6.52, indicates a price-to-GF-Value ratio of 2.31. This suggests that NeuroPace Inc is significantly overvalued according to the GF Value metric.
The GF Value is determined by considering historical trading multiples such as price-earnings ratio, price-sales ratio, price-book ratio, and price-to-free cash flow, along with a GuruFocus adjustment factor based on the company's historical returns and growth, and future business performance estimates from Morningstar analysts.
The insider trend image above reflects the recent selling activity by insiders at NeuroPace Inc, which may be of interest to investors monitoring insider behaviors.
The GF Value image provides a visual representation of the stock's current valuation in relation to its intrinsic value estimate, as calculated by GuruFocus.
This article, generated by GuruFocus, is designed to provide general insights and is not tailored financial advice. Our commentary is rooted in historical data and analyst projections, utilizing an impartial methodology, and is not intended to serve as specific investment guidance. It does not formulate a recommendation to purchase or divest any stock and does not consider individual investment objectives or financial circumstances. Our objective is to deliver long-term, fundamental data-driven analysis. Be aware that our analysis might not incorporate the most recent, price-sensitive company announcements or qualitative information. GuruFocus holds no position in the stocks mentioned herein.
This article first appeared on GuruFocus.
